|
Home:
Educational Supplement: Appendix
Agenda
Wednesday,
November 1
| 7:30
a.m. |
Registration |
| 8:00
a.m. |
Opening
Remarks
Richard D. Klausner, M.D., Director
National Cancer Institute |
| 8:15
a.m. |
Charge
to the Panel
Barnett S. Kramer, M.D., M.P.H., Director
NIH Office of Medical Applications of Research |
| 8:20
a.m. |
Panel and
Conference Chair Remarks
Patricia Eifel, M.D., Professor of Radiation Oncology
M.D. Anderson Cancer Center |
I. Overview
| 8:30
a.m. |
Overview
of Conference
William C. Wood, M.D., FACS, Joseph Brown Whitehead Professor
and Chairman, Department of Surgery
Emory University School of Medicine |
II. Factors
Used To Select Adjuvant Therapy
| 8:45
a.m. |
Factors
Used To Select Adjuvant Therapy—Overview
Gary M. Clark, Ph.D., Professor of Medicine
Baylor Breast Center
Baylor College of Medicine |
| 9:05
a.m. |
Traditional
and Newer Pathological Factors
Stuart J. Schnitt, M.D., Associate Professor of Pathology
Harvard Medical School
Director of Surgical Pathology
Beth Israel Deaconess Medical Center |
| 9:25
a.m. |
Prognostic
and Predictive Role of Proliferation Indices
Maria Grazia Daidone, Ph.D.
Unit 10 Determinants of Prognosis and Treatment Response
Department of Experimental Oncology
Istituto Nazionale Tumori |
| 9:40
a.m. |
Racial/Ethnic
Background and Benefits of Adjuvant Therapy for Breast Cancer
James J. Dignam, Ph.D.
Statistician, National Surgical Adjuvant Breast and Bowel Project |
| 9:55
a.m. |
Patient-Specific
Factors—Young Patients
Aron Goldhirsch, M.D., Chairman, Scientific Committee,
International Breast Cancer Study Group
Professor of Medical Oncology and Director, Division of Medical
Oncology
European Institute of Oncology |
| 10:10
a.m. |
Factors
Used To Select Adjuvant Therapy: An Overview of Age and Race
Hyman B. Muss, M.D., Associate Director, Vermont Cancer
Center
Professor of Medicine, University of Vermont College of Medicine
Director of Hematology/Oncology, Fletcher Allen Health Care
University of Vermont |
| 10:30
a.m. |
Discussion |
III. Adjuvant
Hormone Therapy
| 11:00
a.m. |
Tamoxifen
Sir Richard Peto, F.R.S., M.Sc.
Early Breast Cancer Trialists’ Collaborative Group Secretariat
Professor of Medical Statistics and Epidemiology
Co-Director, ICRF/MRC Clinical Trial Service Unit and Epidemiological
Studies Unit
Radcliffe Infirmary, University of Oxford |
| 11:20
a.m. |
Duration
of Adjuvant Hormonal Treatment
Christina Davies, MBChB, M.Sc., ATLAS Coordinator
Clinical Trial Service Unit, Radcliffe Infirmary
University of Oxford |
| 11:35
a.m. |
Duration
of Adjuvant Tamoxifen Therapy
John L. Bryant, Ph.D., Associate Professor of Biostatistics
University of Pittsburgh
Director, Biostatistical Center
National Surgical Adjuvant Breast and Bowel Project |
| 11:50
a.m. |
Lunch |
| 12:35
p.m. |
Recent
NSABP Adjuvant Studies in Primary (Stage One) Breast Cancer
Bernard Fisher, M.D., Scientific Director
National Surgical Adjuvant Breast and Bowel Project
Distinguished Service Professor
University of Pittsburgh |
| 12:55
p.m. |
Who Should
Not Get Tamoxifen?
C. Kent Osborne, M.D., Professor
Baylor Breast Center
Baylor College of Medicine |
| 1:15
p.m. |
Hormonal
Ablation
Nancy E. Davidson, M.D., Professor
Johns Hopkins Oncology Center
Johns Hopkins University |
| 1:35
p.m. |
Discussion |
IV. Adjuvant
Chemotherapy
| 2:05
p.m. |
Overview:
Progress in Systemic Chemotherapy of Primary Breast Cancer
Gabriel N. Hortobagyi, M.D., FACP, Professor and Chairman
Department of Breast Medical Oncology
M.D. Anderson Cancer Center |
| 2:25
p.m. |
Is HER-2/neu
a Predictor of Anthracycline Utility?—”Pro” Position
Peter Ravdin, M.D., Ph.D., Associate Professor
Department of Medicine, Division of Medical Oncology
University of Texas Health Science Center at San Antonio |
| 2:40
p.m. |
Is HER-2/neu
a Predictor of Anthracycline Utility? No.
George W. Sledge, Jr., M.D., Ballvé-Lantero Professor
of Oncology
Department of Medicine
Indiana University School of Medicine |
| 2:55
p.m. |
Adjuvant
Chemotherapy: Taxanes—the “Pro” Position
I.Craig Henderson, M.D., Adjunct Professor of Medicine
University of California, San Francisco |
| 3:10
p.m. |
NSABP B-28:
Initial Results
Eleftherios P. Mamounas, M.D., Medical Director, Cancer
Center
Aultman Hospital |
| 3:25
p.m. |
Taxanes
in the Adjuvant Setting: Why Not Yet?
Martine J. Piccart, M.D., Ph.D., Chairman, Breast International
Group
Head, Chemotherapy Department
Jules Bordet Institute |
| 3:40
p.m. |
Discussion |
| 4:15
p.m. |
Chemoendocrine
Combined Therapy
Richard Gray, M.A., M.Sc., Director
Clinical Trials Unit
University of Birmingham Medical School |
| 4:35
p.m. |
Preoperative
Chemotherapy
Norman Wolmark, M.D., Chairman, National Surgical Adjuvant
Breast and Bowel Project
Chairman and Professor, Department of Human Oncology
Allegheny General Hospital |
| 4:55
p.m. |
Who Should
Not Receive Chemotherapy?—International Databases
Jonas C. Bergh, M.D., Ph.D., Professor of Clinical and
Molecular Oncology
Karolinska Institute and Hospital |
| 5:10
p.m. |
Who Should
Not Receive Chemotherapy?—U.S. Databases and Trials
Monica Morrow, M.D., Professor of Surgery, Northwestern
Memorial Hospital, Northwestern University Medical School
Director, Lynn Sage Comprehensive Breast Program
Director, Cancer Department, American College of Surgeons |
| 5:25
p.m. |
Discussion |
| 5:55
p.m. |
Adjournment |
Thursday,
November 2
V. Adjuvant
Chemotherapy (continued)
| 8:00
a.m. |
Role of
Dose and Dose Intensity for Chemotherapy
Larry Norton, M.D., Head, Division of Solid Tumor Oncology
Norna S. Sarofim Chair in Clinical Oncology
Memorial Sloan-Kettering Cancer Center |
| 8:20
a.m. |
A Prospective,
Randomized Comparison of Two Doses of Combination Alkyating
Agents (AA) as Consolidation After CAF in High-Risk Primary
Breast Cancer Involving Ten or More Axillary Lymph Nodes (LN):
Preliminary Results of CALGB 9082/SWOG 9114/NCIC MA-13
William P. Peters, M.D., Ph.D., Director and Chief Executive
Officer
Barbara Ann Karmanos Cancer Institute |
| 8:40
a.m. |
Overview
of the Six Randomized Adjuvant Trials of High-Dose Chemotherapy
in Breast Cancer
Karen H. Antman, M.D., Professor of Medicine
College of Physicians and Surgeons of Columbia University
Chief, Division of Medical Oncology
Director, Herbert Irving Comprehensive Cancer Center |
| 9:00 a.m. |
Discussion |
VI. Adjuvant
Postmastectomy Radiotherapy
| 9:30
a.m. |
Overview:
Postmastectomy Radiotherapy
Jack Cuzick, Ph.D., Professor of Epidemiology
Head, Department of Mathematics, Statistics, and Epidemiology
Imperial Cancer Research Fund |
| 9:50
a.m. |
Adjuvant
Postmastectomy Radiotherapy: Review of Treatment Guidelines
and Techniques
Lori Pierce, M.D., Associate Professor
Department of Radiation Oncology
University of Michigan Medical Center |
| 10:10
a.m. |
Discussion |
VII. Influences
of Treatment-Related Side Effects and Quality-of-Life Issues on
Individual Decision-Making About Adjuvant Therapy
| 10:45
a.m. |
Side Effects,
Quality-of-Life Issues, and Tradeoffs: Patient Perspective
Amy S. Langer, M.B.A., Executive Director
National Alliance of Breast Cancer Organizations |
| 11:05
a.m. |
Impact
of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and
Quality of Life
Patricia A. Ganz, M.D., Professor
UCLA Schools of Medicine and Public Health
Director, Division of Cancer Prevention and Control Research
Jonsson Comprehensive Cancer Center |
| 11:20
a.m. |
Chemotherapy
and Combined Chemohormonal Therapy
Eric P. Winer, M.D., Associate Professor of Medicine
Department of Adult Oncology, Dana-Farber Cancer Institute |
| 11:40
a.m. |
Decision-Making
Process—Communicating Risks/Benefits: Is There an Ideal
Technique?
Mark Norman Levine, M.D., Professor of Medicine
McMaster University |
| 12:00
p.m. |
Assessing
Individual Benefit
Alan Coates, M.D., FRACP, International Breast Cancer Study
Group
Chief Executive Officer, Australian Cancer Society |
| 12:20
p.m. |
Discussion |
| 12:50
p.m. |
Adjournment |
Friday, November
3
| 8:00
a.m. |
Registration |
| 9:00
a.m. |
Presentation
of Consensus Development Statement |
| 9:30
a.m. |
Public
Discussion |
| 11:00
a.m. |
Panel Meets
in Executive Session |
| 1:00
p.m. |
Press Conference |
| 2:00
p.m. |
Adjournment |
|
|
